Rationale design and objectives of two phase III randomised placebo-controlled studies of GLPG1690 a novel autotaxin inhibitor in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

摘要

IntroductionWhile current standard of care (SOC) for idiopathic pulmonary fibrosis (IPF) slows disease progression, prognosis remains poor. Therefore, an unmet need exists for novel, well-tolerated agents that reduce lung function decline and improve quality of life. Here we report the design of two phase III studies of the novel IPF therapy, GLPG1690.